https://www.selleckchem.com/pr....oducts/elamipretide-
At 1.5 years after acquisition, prices paid to private equity dermatologists for routine medical visits were 3-5 percent higher than those paid to non-private equity dermatologists. There was no significant consistent impact on dermatology spending or use of biopsies, lesion destruction, or Mohs surgery. Policy makers and dermatology practice leaders may want to track the rapidly evolving phenomenon of private equity acquisitions.In recent years direct ownership of physician practices by hospitals and health systems (that i
Curtir
Comentario
Compartilhar
